Application | (3Z,6Z)-3-[(5-tert-butyl-1h-imidazol-4-yl) methylene]-6-(benzylidene)-2, 5-piperazinedione, also known as Plinabulin(KPU-2,NPI-2358), was developed by Nereus pharmaceutical company, USA, it is a synthetic derivative of the low-molecular-ring dipeptide phenylahistin or halimide derived from marine Aspergillus, and is a tubulin-binding agent. |
biological activity | plinablin (NPI-2358) is a vascular disrupting agent (VDA), it acts on tumor cells and affects tubulin depolymerization, with IC50 of 9.8-18 nM. Phase 1/2. |
Target | TargetValue Tubulin 9.8 nM-18 nM |
Target | Value |
Tubulin
| 9.8 nM-18 nM |
in vitro study | NPI-2358 binds to the colchicine binding site of tubulin to effectively inhibit human tumor cell lines over-expressing Pgp, or reduce the catalytic activity of nuclear Topo II, IC50 9.8 to 18 nM. NPI-2358 concentration of 20 nM on human umbilical vein endothelial cells can rapidly induce tubulin depolymerization, and through the single cell layer. NPI-2358 acts on MM cells to stop the MM cells at the early stage of mitosis and induce cell death. NPI-2358 also inhibits microtubule formation, and migration of endothelial cells and MM cells, causing tumor vasculature to malfunction. NPI-2358 can induce cell death, does not affect the viability of other normal monocytes. NPI-2358 induces mitotic arrest or MM cell death, but blocking the JNK pathway can inactivate this induction. |
in vivo study | NPI-2358(7.5 mg/kg) inhibited tumor growth in mice bearing human plasma cell xenografts. NPI-2358 induced a decrease in tumor perfusion in a time and dose dependent manner. NPI-2358 acting on KHT sarcoma is more effective than acting on C3H tumor, and radiation treatment can enhance the anticancer activity of the two tumors. |